Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer
NCT04659785Phase 2Unknown
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Jul 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluzoparib in small cell lung cancer (SCLC), sponsored by The Second Hospital of Tianjin Medical University. Primary endpoints: Recommended Phase II Dose at 28 days, Incidence of Adverse Events at 28 days and 1 more. Status: unknown.
02
Drugs
fluzoparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04659785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04659785.